Characteristics | cDMARD, n = 1400 | TNFi, n = 3094 | IFX, n = 642 | ETN, n = 1245 | ADA, n = 1207 | RTX, n = 438 | p* |
---|---|---|---|---|---|---|---|
Age | 62 (53–72) | 54 (45–61) | 52 (44–59) | 54 (45–61) | 55 (47–62) | 59 (52–67) | < 0.001 |
Female sex | 69 | 75 | 72 | 76 | 76 | 77 | < 0.001 |
Time from diagnosis, yrs | 9.4 (5.0–13) | 11 (6.0–19) | 11 (5.8–17) | 11 (5.8–19) | 12 (6.4–20) | 15 (8.7–23) | < 0.001 |
Beginning of followup, yr | 2009 (2008–2010) | 2006 (2004–2008) | 2003 (2002–2007) | 2006 (2004–2009) | 2006 (2005–2008) | 2009 (2008–2010) | < 0.001 |
RF-positive | 65 | 78 | 78 | 77 | 78 | 88 | < 0.001 |
DAS28 | 3.2 (2.2–4.3) | 4.4 (3.2–5.5) | 4.8 (3.6–5.8) | 4.2 (3.0–5.3) | 4.3 (3.2–5.4) | 4.5 (3.3–5.4) | < 0.001 |
HAQ-DI | 0.8 (0.28–1.4) | 1.0 (0.50–1.5) | 1.1 (0.62–1.7) | 1.0 (0.50–1.5) | 1.0 (0.48–1.5) | 1.1 (0.6–1.7) | < 0.001 |
Prior malignancy | 5.5 | 3.2 | 3.0 | 3.3 | 3.3 | 10 | < 0.001 |
Hospitalization because of an infection during past 24 mos | 3.6 | 4.0 | 4.2 | 3.9 | 3.9 | 7.8 | < 0.001 |
Baseline use of MTX | 75 | 54 | 54 | 54 | 56 | 41 | < 0.001 |
Baseline use of sulphasalazine | 31 | 22 | 22 | 22 | 22 | 17 | < 0.001 |
Baseline use of HCQ | 41 | 28 | 28 | 28 | 28 | 25 | < 0.001 |
Baseline use of oral corticosteroids | 53 | 75 | 78 | 75 | 73 | 78 | < 0.001 |
Prior biologic | 0 | 31 | 12 | 37 | 36 | 63 | > 0.001 |
Prior TNFi | 0 | 30 | 12 | 36 | 35 | 61 | < 0.001 |
Prior biologic other than TNFi | 0 | 2.1 | 1.6 | 2.6 | 1.8 | 6.4 | < 0.001 |
1 prior biologic | 0 | 25 | 5.0 | 32 | 28 | 26 | < 0.001 |
More than 1 prior biologic | 0 | 6.1 | 7.0 | 4.6 | 7.2 | 36 | < 0.001 |
Duration of prior biologic treatment ≥ 1.60 yrs | 0 | 14 | 4.4 | 16 | 18 | 40 | < 0.001 |
↵* Pooled TNFi column excluded from baseline statistical comparison. IQR: interquartile range; cDMARD: conventional disease-modifying antirheumatic drug; TNFi: tumor necrosis factor inhibitors; IFX: infliximab; ETN: etanercept; ADA: adalimumab; RTX: rituximab; RF: rheumatoid factor; DAS28: Disease Activity Score at 28 joints; HAQ-DI: Health Assessment Questionnaire–Disability Index; MTX: methotrexate; HCQ: hydroxychloroquine.